StockData
Biogen Inc. logo

Biogen Inc. (BIIB) stock

BIIBNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 28, 2026Score 4/3056% above fair value
$250.79−0.86 (-0.34%)

Close on Nov 17, 2026Market cap $37.07BP/E 107.2Yield –

Biogen enterprise value

Enterprise value is market cap plus debt, minus cash: the value of the whole business to all its investors.

Biogen's enterprise value was $36.23B on Nov 11, 2026, against $22.72B a year earlier. Over the last 5 years it ranged from $15.74B to $45.19B, with a median of $30.79B.

Enterprise Value at the end of each year

PeriodPeriod endValueChange
2026Nov 11, 2026$36.23B+66.0%
2025Dec 31, 2025$21.82B+5.8%
2024Dec 31, 2024$20.62B-41.6%
2023Dec 29, 2023$35.29B-1.0%
2022Dec 30, 2022$35.66B+5.5%
2021Dec 31, 2021$33.78B-9.6%
2020Dec 31, 2020$37.38B-29.2%
2019Dec 31, 2019$52.82B-9.3%
2018Dec 31, 2018$58.22B-13.4%
2017Dec 29, 2017$67.26B+11.7%
2016Dec 30, 2016$60.23B-11.3%
2015Dec 31, 2015$67.92B-14.5%
2014Dec 31, 2014$79.43B+19.9%
2013Dec 31, 2013$66.25B+89.7%
2012Dec 31, 2012$34.92B+26.6%
2011Dec 30, 2011$27.59B+42.2%
2010Dec 31, 2010$19.41B+27.0%
2009Dec 31, 2009$15.29B–

More Biogen figures

See a number that looks wrong?